Logo

Aclara BioSciences Second Quarter Revenues Drop

Jul 30, 2003

NEW YORK, July 30 -- Aclara BioSciences of Mountain View, Calif., today announced revenues of $405,000 for the second quarter ending June 30, compared to $673,000 for the year-ago quarter.

 

The company reported research and development expenditures of $4.1 million, compared to $6.6 million for the same quarter in 2002.

 

The firm reported cash, cash equivalents, and short term investments of $73.6 million, compared to the $51 million it reported as of Dec. 31.

 

The company had a net loss of $5.1 million, compared to $9.9 million for the year-ago period.

 

The company said it reduced operating expenses by $5.6 million, with $3.8 million in savings from the reduction of its microfluidics programs, a reorganization, and a decision to focus on its eTag Assay product line. The firm also saved $1.8 million by eliminating settlement expenses.

 

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.